ALDX — Aldeyra Therapeutics, Inc. Stock Price, Chart & AI Report

Negative Apr 15, 2026 • 20:53 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit covers investors who purchased securities between November 3, 2023 and March 16, 2026. The firm alleges that trial results were inconsistent and unreliable.

ALDX class action lawsuit securities fraud clinical trial results misleading statements investor losses reproxalap

Sentiment note

The company is the subject of a class action lawsuit alleging false and misleading statements about clinical trial results, which undermines investor confidence and indicates potential securities fraud and financial losses for shareholders.

Negative Apr 13, 2026 • 18:56 UTC GlobeNewswire Inc. • Levi & Korsinsky, Llp

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

Aldeyra Therapeutics faces a securities class action lawsuit alleging the company misrepresented reproxalap clinical trial data as consistent and reliable when internal data showed inconsistencies. The FDA's March 2026 Complete Response Letter revealed the trial results were unreliable and lacked substantial evidence of effectiveness, causing ALDX stock to collapse 70.7%. The class period runs from November 3, 2023 to March 16, 2026, with a lead plaintiff deadline of May 29, 2026.

ALDX securities fraud class action lawsuit clinical trial data FDA Complete Response Letter reproxalap stock collapse investor losses

Sentiment note

Company allegedly concealed inconsistent clinical trial data for reproxalap while making confident public statements about its efficacy and safety. Stock collapsed 70.7% following FDA disclosure of unreliable trial results. Securities fraud lawsuit filed with significant investor losses.

Negative Apr 12, 2026 • 14:41 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Rosen Law Firm has filed securities class action lawsuits against Aldeyra Therapeutics, Trip.com Group Limited, and Alight, Inc., alleging that defendants made false and misleading statements regarding business operations and prospects. Investors with losses exceeding $100,000 are encouraged to join the class actions before the respective deadlines.

ALDX TCOM ALIT securities class action false statements investor losses lead plaintiff deadline clinical trial results

Sentiment note

Company is defendant in securities class action lawsuit alleging false and misleading statements about reproxalap clinical trial results and business prospects, resulting in investor losses.

Negative Apr 12, 2026 • 14:01 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, THE FIRST FILING FIRM, Encourages Trip.com Group Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOM

Rosen Law Firm has filed securities class action lawsuits against Trip.com Group Limited, Aldeyra Therapeutics, Inc., and Alight, Inc., alleging that defendants made false and misleading statements or failed to disclose material information. Investors with losses exceeding $100,000 are encouraged to secure counsel before the May 11, 2026 lead plaintiff deadline.

TCOM ALDX ALIT securities class action Trip.com Group Limited Aldeyra Therapeutics Alight Inc. investor losses

Sentiment note

Company is defendant in securities class action lawsuit filed by Rosen Law Firm, with investors experiencing losses exceeding $100,000.

Negative Apr 10, 2026 • 18:53 UTC GlobeNewswire Inc. • The Schall Law Firm

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against Aldeyra Therapeutics for securities fraud. The company allegedly made false and misleading statements about its reproxalap drug candidate, with clinical trial results showing inconsistencies. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to participate before the May 29, 2026 deadline.

ALDX securities fraud class action lawsuit Aldeyra Therapeutics reproxalap clinical trials misleading statements investor losses

Sentiment note

The company is facing a securities fraud lawsuit alleging false and misleading statements about clinical trial results for its drug candidate reproxalap. Investors suffered damages when the market learned the truth about the inconsistencies, indicating significant corporate misconduct and loss of investor confidence.

Negative Apr 9, 2026 • 18:52 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING AND RANKED FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Rosen Law Firm has filed a securities class action lawsuit against Aldeyra Therapeutics, alleging the company made false and misleading statements regarding reproxalap clinical trial results. The lawsuit claims trial results were inconsistent and unreliable, and that defendants' statements about the company's business and prospects lacked a reasonable basis. The lead plaintiff deadline is May 29, 2026.

ALDX securities class action Aldeyra Therapeutics reproxalap clinical trial results misleading statements investor lawsuit lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about clinical trial results for its drug candidate reproxalap. The allegations suggest inconsistent and unreliable trial data, which undermines investor confidence and indicates potential fraud or misrepresentation.

Negative Apr 8, 2026 • 16:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. alleging that the company made false and misleading statements about reproxalap clinical trial results. The complaint claims trial results were inconsistent and unreliable, rendering statements about the company's business and prospects materially false. Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible to join the lawsuit.

ALDX class action lawsuit securities fraud clinical trial results reproxalap investor harm misleading statements

Sentiment note

The company is accused of making false and misleading statements about clinical trial results for its drug candidate reproxalap. Allegations of inconsistent trial results and lack of reliable positive findings indicate potential fraud and misrepresentation to investors, resulting in investor losses.

Negative Apr 6, 2026 • 20:00 UTC GlobeNewswire Inc. • Levi & Korsinsky, Llp

ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Omitted Inconsistent Trial Data: Levi & Korsinsky

Aldeyra Therapeutics faces a securities class action lawsuit alleging the company made misleading statements about reproxalap clinical trial results between November 2023 and March 2026. The FDA's Complete Response Letter revealed that trial data was inconsistent and unreliable, causing the stock to collapse 70.7%. Investors who purchased ALDX stock during the class period may seek recovery, with a lead plaintiff deadline of May 29, 2026.

ALDX securities fraud class action lawsuit clinical trial data FDA reproxalap misleading statements investor losses

Sentiment note

Company is accused of securities fraud for allegedly omitting inconsistent clinical trial data and making false statements about reproxalap's efficacy and safety. Stock collapsed 70.7% following FDA disclosure of unreliable trial results. Multiple regulatory and legal issues indicate severe reputational and financial damage.

Negative Apr 6, 2026 • 18:32 UTC GlobeNewswire Inc. • Robbins Llp

ADLX Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

Robbins LLP announced a class action lawsuit against Aldeyra Therapeutics for allegedly misleading investors about its lead drug candidate reproxalap. The FDA issued a Complete Response Letter on March 17, 2026, stating the drug failed to demonstrate efficacy for dry eye disease treatment and citing inconsistent clinical trial results. Aldeyra's stock price dropped 70.7% following the announcement. The lead plaintiff deadline is May 29, 2026.

ALDX class action lawsuit Aldeyra Therapeutics reproxalap FDA Complete Response Letter clinical trial failure investor fraud stock price decline

Sentiment note

The company is accused of misleading investors about clinical trial results for its lead drug candidate. The FDA rejected the drug application citing lack of efficacy and inconsistent study results. The stock experienced a severe 70.7% price decline following the rejection announcement, indicating significant loss of investor confidence.

Negative Apr 6, 2026 • 00:57 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Rosen Law Firm has filed a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023 and March 16, 2026. The lawsuit alleges that defendants made false and misleading statements regarding reproxalap clinical trial results, claiming the results were inconsistent and unreliable, thereby misrepresenting the company's business and prospects. Investors who wish to serve as lead plaintiff must file by May 29, 2026.

ALDX class action lawsuit securities fraud clinical trial results reproxalap misleading statements investor compensation

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding clinical trial results for its drug candidate reproxalap. The allegations of false and misleading statements about business operations and prospects, combined with inconsistent trial results, indicate serious regulatory and reputational concerns for investors.

Negative Apr 3, 2026 • 14:57 UTC GlobeNewswire Inc. • The Schall Law Firm

ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors to join a class action lawsuit against Aldeyra Therapeutics for securities fraud. The company allegedly made false and misleading statements about its reproxalap drug candidate, with clinical trial results showing inconsistencies. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to participate before the May 29, 2026 deadline.

ALDX securities fraud class action lawsuit Aldeyra Therapeutics reproxalap clinical trials misleading statements investor losses

Sentiment note

The company is accused of making false and misleading statements about its reproxalap drug candidate, with clinical trial results showing inconsistencies. This resulted in investor losses and triggered a securities fraud class action lawsuit.

Negative Apr 3, 2026 • 00:09 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX

Rosen Law Firm has filed a securities class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023 and March 16, 2026. The lawsuit alleges that defendants made false and misleading statements regarding reproxalap clinical trial results, claiming the results were inconsistent and unreliable. Investors who wish to serve as lead plaintiff must file by May 29, 2026.

ALDX securities class action Aldeyra Therapeutics reproxalap clinical trials misleading statements investor lawsuit lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about clinical trial results for its drug candidate reproxalap. The allegations of inconsistent trial results and lack of reliable findings indicate potential fraud and misrepresentation to investors, resulting in investor damages.